Board Recruitment by Occam Global for Clinical Stage Oncology Innovator
Recruitment of Serial CEO to Board for Clinical-Stage Oncology Innovator
In October 2024, Occam Global recruited Jayson Dallas, MD to the Board of Faeth Therapeutics, a clinical-stage precision oncology company whose founding team includes Lew Cantley and Sid Mukherjee, leading experts in the field of cancer metabolism, functional genomics, and tumor metabolism.
Dallas himself is an accomplished commercial executive and serial CEO who brings rich experience across clinical development, medical affairs, commercial strategy and business development. He currently serves as CEO of Rivus Pharmaceuticals, a clinical-stage company targeting cardio metabolic disease.
Dallas joined Rivus from Aimmune Therapeutics, where, as CEO, he oversaw the first-ever approval and launch of a food allergy therapeutic, culminating in a $2.1BN sale to Nestlé Health Science. Prior to Aimmune, Dallas served as Chief Commercial of Ultragenyx Pharmaceuticals. His earlier career entailed several senior positions at Genentech / Roche and Novartis.
About Faeth Therapeutics
Faeth Therapeutics focuses on developing cancer treatments by targeting the unique metabolic dependencies of cancer cells. Using insights from computational biology and machine learning, they analyze the specific metabolic pathways that fuel tumor growth. This approach allows Faeth to design therapies that disrupt multiple key metabolic points within cancer cells, aiming to weaken or eliminate their ability to proliferate.
In addition to their scientific innovation, Faeth offers a patient-centric experience through their app, which helps patients adhere to treatment protocols by customizing their nutritional and metabolic support. Their clinical trials incorporate this targeted metabolic approach, providing patients with personalized guidance to maximize the effectiveness of these therapies. This approach represents a shift in oncology by addressing cancer metabolism as a means to improve treatment outcomes.
Click here to learn more about our life science executive search case studies.
Recent Placements
- Avirup Bose, Ph.D., as Chief Business Officer of Iktos
- Steve Harrison as CSO at Nucleome
- Aimee Einstein as VP of People & Culture at SI-BONE
- David Brower as CBO for Oncology Biotech Accent Therapeutics
- Annette Matthies as CBO at Elicio Therapeutics
- Steve Staben as CSO at Lycia Therapeutics
- David Southwell placed as Chairman of Revolo Biotherapeutics
- Adrian Schreyer placed as CTO of Anagenex
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.